Posted by Michael Wonder on 15 Jun 2024
Extremely rare disease drug Ceprotin clears major hurdle to reimbursement
14 June 2024 - Ceprotin (protein C concentrate), an ultra-rare disease treatment developed by Takeda Pharmaceutical Korea, has passed the Pharmaceutical Reimbursement Evaluation Committee (PREC) review, passing the 80% mark in getting insurance coverage.
Takeda Pharmaceuticals Korea also overturned the outcome of the previous review by filing an objection against PREC, which rejected the expansion of the reimbursement standard for Zejula (niraparib) last month.
